Roche’s Tecentriq to be filed for early-stage liver cancer

A regimen of Roche’s Tecentriq and Avastin has become the first immunotherapy-based combination to reduce the risk of liver cancer returning after surgery to remove the tumour in a phase 3 trial, according to the company.